Black Diamond Therapeutics, Inc.
NASDAQ:BDTX
Overview | Financials
Company Name | Black Diamond Therapeutics, Inc. |
Symbol | BDTX |
Currency | USD |
Price | 2.3 |
Market Cap | 130,145,730 |
Dividend Yield | 0% |
52-week-range | 2.09 - 7.66 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Dr. Mark A. Velleca M.D., Ph.D. |
Website | https://www.blackdiamondtherapeutics.com |
An error occurred while fetching data.
About Black Diamond Therapeutics, Inc.
Black Diamond Therapeutics, Inc., a biotechnology company, discover, develops, and commercializes medicines for patient with genetically defined tumors. It develops BDTX-189, an irreversible small molecule inhibitor that is designed to targets oncogenic proteins defined by the non-canonical epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 driver
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD